FDA On What Aduhelm AdCom Got Wrong: Statistics, Investigational Drugs, Patient Perspective

 
• By Brenda Sandburg
  
Alzheimer's
FDA answers critics in review documents for Alzheimer's disease drug Aduhelm • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards